重组人甲状旁腺素1-34联合钙尔奇D治疗绝经后女性骨质疏松疗效观察

目的 研究重组人甲状旁腺素1-34(recombinant human parathyroid hormone 1-34,rhPTH1-34)联合钙尔奇D治疗绝经后妇女骨质疏松的治疗效果.方法 84例绝经后骨质疏松妇女被随机分为实验组和对照组,每组均有患者42例.实验组采用rhPTH1 34)联合钙尔奇D治疗,对照组仅采用钙尔奇D治疗,疗程均为6个月.观察两组患者治疗前后骨密度变化、血清钙、磷和碱性磷酸酶(Alkaline Phosphatase,ALP)、骨痛症状变化和治疗期间的骨折发生率.结果实验组治疗后的骨密度(T值)较治疗前增加,差异具有统计学意义(P<0.05);并且实验组治疗后的骨密度(T值)较对照组治疗后的骨密度(T值)增加,差异具有统计学意义(P<0.05).实验组和对照组治疗后ALP的浓度均高于治疗前,差异具有统计学意义(P<0.05),并且实验组治疗后ALP的浓度高于对照组治疗后,差异具有统计学意义(P<0.05).实验组的骨痛治疗有效率为66.67%;对照组为50%,实验组的有效率高于对照组,差异具有统计学意义(χ2=4.04,P<0.05).结论 rhPTH1 34联合钙尔奇D能够有效的提高绝经后女性的骨密度,减少骨质疏松的症状.

Clinical efficacy observation of recombinant human parathyroid hormone 1-34(rhPTH1-34)combined with caltrate D in treatment of post-menopausal women with osteoporosis

Objective To investigate the therapeutic effects of recombinant human parathyroid hormone 1-34(rhPTH1-34)combined with Caltrate D on post-menopausal women with osteoporosis.Methods Eighty-four post-menopausal women into osteoporosis were divided randomly into experimental group and control group,each group with 42 cases.The experimental group was treated with rhPTH1-34 combined with Caltrate,while the control group was treated with Caltrate D.The treatment course of the two groups were 6 months.The bone mineral density,serum calcium,phosphorus and alkaline phosphatase(Alkaline phosphatase,ALP)before and after treatment,the bone pain symptom change and treatment during the fracture rate in the two groups of patients were observed.Results After the treatment,the bone mineral density(T value)in the experimental group was increased compared with that before treatment,with significant difference(P<0.05);after the treatment,the bone mineral density(T value)in the experimental group was also increased compared with the control group,with significant difference(P<0.05).After treatment,the ALP concentrations on the experimental group and control group were increased compared with those before treatment,with significant difference(P<0.05),and the experimental group was increased compared with the control group after treatment,with significant difference(P<0.05).The rate of bone pain treatment efficacy in the experimental group was 66.67%;that in the control group was 50%,which showed a significant difference(χ2 =4.04,P< 0.05).Conclusion rhPTH1-34 combined with Caltrate D treatment can increase bone mineral density and relieve symptoms on post-menopausal women with osteoporosis.